Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


One Boston Scientific warning letter down

This article was originally published in The Gray Sheet

Executive Summary

Guidant's December 2005 FDA warning letter blocking PMA approvals for certain cardiac rhythm management devices is lifted April 16 following resolution of quality system deficiencies at Boston Scientific's St. Paul, Minn. CRM facility, acquired from Guidant last year. With the regulatory restrictions removed, Boston Scientific gained five approvals for software upgrades and enhancements to CRM products on April 17. The same day, the firm also announced FDA approval of its Acuity steerable left ventricular lead, expected to launch in July for use with cardiac resynchronization devices. Boston Scientific plans to be ready for inspections related to its January 2006 corporate quality systems warning letter by June (1"The Gray Sheet" Feb. 5, 2007, p. 6)...

You may also be interested in...

Boston Scientific Sees CRM Pipeline Aiding ICD Market Share Gains

Boston Scientific is highlighting recent and near-term product introductions as a key component of its plan to boost market share in its cardiac rhythm management business

Boston Scientific’s Improving ICD Sales Offset Slow Stent Revenues In Q1

Boston Scientific's recent resolution of a warning letter pertaining to quality control deficiencies at one of its cardiac rhythm management device manufacturing plants should help increase sales of the implants in the coming quarters, the firm says

Boston Scientific Expects To Be Ready For FDA Inspections By Summer

Boston Scientific says it will be ready by the end of the second quarter to begin FDA inspections that will resolve a year-old, corporate-wide quality systems warning letter

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts